Clare T. Butler
Dublin, L, Ireland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Mechanistic modeling of generic orally inhaled drug products: A workshop summary report.
Journal: CPT: pharmacometrics & systems pharmacology
Published: August 25, 2022
Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors.
Journal: BMC cancer
Published: May 18, 2020
1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours.
Journal: Oncotarget
Published: January 01, 2019
A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Journal: The Journal of biological chemistry
Published: July 27, 2016
Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer.
Journal: Frontiers in cell and developmental biology
Published: July 14, 2016
Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.
Journal: Scientific reports
Published: February 08, 2016
Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis.
Journal: The Journal of biological chemistry
Published: December 16, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026